

- Member race and ethnicity is sourced from the California Healthcare Eligibility, Enrollment, and Retention System (CalHEERS).
- Health Evidence Initiative (HEI) data excludes Covered California for Small Business (CCSB), includes only Qualified Health Plan (QHP) submitted claims.
- Measure results from HEI data may differ slightly from measure results from Quality Rating System (QRS) data because they include allowable adjustments resulting in small changes to measure specifications.
- Total rates are not displayed for measures stratified by race and ethnicity due to small discrepancies compared to publicly reported HEDIS and QRS measure rates, resulting from HEI data characteristics outlined above.
- All HEI-sourced rates are subject to a quality assurance process including assessing year-over-year results, comparison to QRS publicly reported results where applicable and other industry norms.
- Rates with fewer than 11 cases in the numerator have been suppressed to comply with the Health Insurance Portability and Accountability Act of 1996 (HIPAA) Privacy Rule's de-identification standard.
- Rates with fewer than 30 cases in the denominator have been suppressed because such small rates can be unreliable.

BEHAVIORAL HEALTH

HEALTHCARE EVIDENCE INITIATIVE (HEI) MEASURE RESULTS

Performance Metrics

HEALTH CARE INITIATIVE (HEI)

PERFORMANCE MEASURE	PAGE
Pharmacotherapy for Opioid Use Disorders	4

Pharmacotherapy for Opioid Use Disorders (NQF #3400)



	Plan Product	MY2019	MY2020	MY2021
Anthem	EPO	43%	50%	52%
Blue Shield	HMO	33%	34%	37%
	PPO	39%	42%	44%
Chinese Community	HMO	Too Few Members	Too Few Members	Too Few Members
Health Net	EPO	Too Few Members	Too Few Members	Too Few Members
	HMO	23%	25%	31%
	PPO	42%	45%	57%
Kaiser Permanente	HMO	55%	59%	55%
LA Care	HMO	25%	20%	29%
Molina Healthcare	HMO	16%	18%	22%
Oscar Health Plan	EPO	31%	32%	29%
Sharp Health Plan	HMO	23%	24%	23%
Valley Health Plan	HMO	Too Few Members	Too Few Members	Too Few Members
Western Health Advantage	HMO	28%	25%	29%

- Percentage of members ages 18-64 with an Opioid Use Disorder (OUD) who got medication treatment for their opioid disorder during the measurement year
- Medication is a critical part of treatment for individuals with OUD; this measure includes the following four types of Food and Drug Administration-approved drug products:
 - Buprenorphine
 - Oral naltrexone
 - Long-acting, injectable naltrexone
 - Methadone
- Individuals who engage in treatment with medication are less likely to exhibit withdrawal or craving symptoms, and more likely to engage in mental health therapy
- Indicator: Higher is better